Medical Education:

Professional Memberships: Sahaya International, SAATHII

Dr. Van Rompay is specialized in using the SIV/infant macaque model of pediatric AIDS to look at the different aspects of viral pathogenesis and the effects of antiviral drug treatment (prophylaxis, therapy, drug resistance and long-term toxicity). In collaboration with Dr. Marthas, he is also involved in using this infant model for vaccine research.

The main goal of his research is to find simple and affordable intervention strategies that can make a difference, especially for developing countries. Because no HIV vaccine is available, proper knowledge, education and social development are still the best weapons. Therefore, he is also involved with the HIV epidemic in developing countries at the grassroot level. He is the founder and secretary of a nonprofit organization, Sahaya International (http://www.sahaya.org), that helps to support NGO's, medical programs and orphan care programs in India and several countries in Africa.

Selected Publications: Van Rompay, K.K.A., J.L. Greenier, K. Stefano-Cole, P. Earl, B. Moss, J.D. Steinbeck, b. Pahar, T. Rourke, R.C. Montelaro, D.R. Canfield, R.P. Tarara, C.J. Miller, M.B. McChesney, M.L. Marthas. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virology. 77: 179-190. 2003.

Van Rompay K.K.A., Mathews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC, North TW. 2002. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J. Virol; 76: 6083-6092.

Van Rompay K. K. A., McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. 2001. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis; 184:429-438.

Van Rompay K. K. A., Miller MD, Marthas ML, et al. 2000. Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol ; 74:1767-1774.

Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, P. D. Lamy, et al. 1999. 9-[2-(Phosphonomethoxy) propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus virus with reduced susceptibility to PMPA. Antimicrob. Agents & Chemotherapy 43: 802-812.

Van Rompay, K. K. A., P. J. Dailey, R. P. Tarara, D. R. et al. 1999. Early short-term 9-[2-(phosphonomethoxy)-propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 73: 2947-2955.

Van Rompay, K. K. A., C. J. Berardi, N. L. Aguirre, N. Bischofberger, P. S. Lietman, N. C. Pedersen, and M. L. Marthas. 1998. Two doses of 9-[2-(phosphonomethoxy)-propyl]adenine (PMPA) protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998; 12: F79-F83.

Van Rompay, K. K. A., M. L. Marthas, J. D. Lifson, et al. 1998. Administration of 9-[2-(phosphonomethoxy)- propyl]-adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res. Hum. Retroviruses 1998; 14: 761-773.

Van Rompay, K. K. A., C. J. Berardi, S. Dillard-Telm, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis., 1998; 177: 1247-1259.

Van Rompay, K. K. A., et al. Zidovudine-resistant simian immunodeficiency virus with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob. Agents Chemother., 1997; 41: 278-283.